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Abstract. The 42 amino acid form of amyloid  (A42) plays a key role in the 
pathogenesis of Alzheimer’s disease (AD) and is a core biomarker for the diagnosis of 
AD. Numerous studies have shown that cerebrospinal fluid (CSF) A42 concentrations 
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are decreased in AD, when measured by enzyme-linked immunosorbent assay 
(ELISA) and other conventional immunoassays. While most studies report no change 
in plasma A42, independent studies using the immunomagnetic reduction (IMR) 
technique report an increase in plasma A42 levels in AD. To confirm the opposite 
changes of A42 levels in CSF and plasma for AD, we assayed the levels of A42 in 
plasma of subjects with known CSF A42 levels. In total 43 controls and 63 AD 
patients were selected at two sites: the VU University Medical Center (n = 55) and 
Sahlgrenska University Hospital (n = 51). IMR and ELISA were applied to assay A42 
in plasma and CSF, respectively. We found a moderately negative correlation between 
plasma and CSF A42 levels in AD patients (r = -0.352), and a weakly positive 
correlation in controls (r = 0.186). These findings further corroborate that there are 
opposite changes of A42 levels in CSF and plasma in AD. The possible causes for the 
negative correlation are discussed by taken assay technologies, A42 transport from 
brain to peripheral blood, and sample matrix into account.  
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There is a strong demand for fluid-based biomarkers for Alzheimer’s disease 
(AD) in both the research and clinical context, with applications in clinical diagnosis, 
developing AD-related drugs, and as screening tools in clinical trials, for example in 
the pre-screen of patients for amyloid positron emission tomography (PET) [1-8]. 
Quantifications of cerebrospinal fluid (CSF) biomarkers such as A42, total tau (t-Tau) 
and phosphorylated tau (p-Tau) proteins have been incorporated into standard 
diagnostic guidelines for AD [1,2]. It has been demonstrated that the change in CSF 
A42 level happens 10-20 years earlier than the onset of clinical symptoms [3,4]. The 
CSF A42 level was found to be significantly reduced in individuals with AD [5-9]. 
For inclusion of A42 analysis as the first step in a multiple process to screen 
preclinical AD, it is important to be able to measure it with a low cost and 
non-invasive method, such as blood analysis. However, the AD-related biomarkers in 
blood are very low abundant and thus ultra-sensitive assay technologies are needed to 
measure AD-related biomarkers in blood samples. This demand motives numerous 
groups to develop ultra-sensitive assays. Several technologies for peripheral blood 
analysis have been developed, such as single-molecule array (Simoa), single-molecule 
counting (SMC), multi-analyte profiling (xMAP) and mass spectrometry (MS)-based 
quantification [10-15]. So far, the results have been inconsistent showing increased, 
unchanged or decreased plasma A42 concentrations in AD and no overall significant 
change upon meta-analysis [16]. The low levels of A42 in blood together with its 
short half life and matrix effects pose strong requirements on the methodologies [17]. 
An ultra-sensitive immunoassay with high sensitivity and low interference 
called immunomagnetic reduction (IMR) assay was developed to quantify blood A42 
level [18,19]. According to the results in a Taiwanese cohort, blood A42 level 
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measured using IMR is approximately 15 pg/ml in healthy elderly individuals [20]. 
Interestingly, blood A42 levels are increased in early AD (specifically mild cognitive 
impairment (MCI) due to AD and mild AD in the two studies) [20,21]. Importantly, 
higher blood A42 level in AD patients than healthy control was also observed in 
study based on a US patient cohort [22]. The good consistency between the studies in 
Taiwan and US shows the high reliability and promising utilities of blood-based 
biomarkers for both research and clinical uses of AD using IMR assay.  
According to the published reports by independent groups, significant changes 
in A42 level in both CSF and in plasma in AD were found, but with an opposite 
change in A42 between CSF (reduced levels) and plasma (higher levels), which 
implies that there is an inverse correlation for A42 between CSF and plasma. 
However, the cohorts in the CSF studies were different from the above studies, 
precluding the possibility to directly correlate A42 levels between CSF and plasma in 
the same cohort. Therefore, in the present study, the levels of plasma A42 (measured 
with IMR) were directly compared and correlated with those in CSF (measured with 
ELISA) in the same cohort, that included 106 samples from 63 AD patients and 43 
controls from two independent sites. In addition to examining the correlation in A42 
level between CSF and plasma, possible factors contributing to the correlation are 
discussed. 
 
MATERIALS AND METHODS 
Study populations 
Two sites enrolled subjects and analyzed CSF A42. The first site was the 
Clinical Neurochemistry Laboratory, Sahlgrenska University, Mölndal, Sweden, and 
the samples consisted of de-identified CSF samples from clinical diagnostic routine, 
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following procedures approved by the Ethical Committee at University of Gothenburg. 
The AD group included patients with cognitive deterioration who had pathological 
CSF AD core biomarker levels using optimized cut-off levels for AD, specifically 
Aβ1-42 < 530 pg/ml, t-tau > 350 pg/ml, and p-tau > 60 pg/ml [23]. The control group 
included patients with minor psychiatric or neurological complaints, but with normal 
basic CSF tests (cell count, CSF/serum albumin ratio, IgG and IgM index), thereby 
excluding disorders affecting the blood-brain barrier function, including inflammatory 
CNS disorders [10], together with normal levels of the core AD biomarkers. 
The second site wasthe Alzheimer Center at VU University Medical Center. We 
selected 53 patients (n = 34 AD patients and n = 19 controls) from the Amsterdam 
Dementia Cohort [24]. All patients underwent standard dementia screening at baseline, 
including physical and neurological examination, electroencephalogram (EEG), 
magnetic resonance imaging (MRI) and laboratory tests. Cognitive screening included 
at least a Mini Mental State Examination (MMSE). Diagnoses were made by 
consensus in a multidisciplinary team without knowledge of CSF results. The 
diagnosis of SCD was given when the results of all clinical examinations and test 
results were normal, i.e., when the criteria for MCI or AD were not fulfilled, and there 
was no psychiatric diagnosis. The SCD patients served as a control in this study. All 
probable AD patients met the core clinical NIA-AA criteria [1]. All subjects gave 
written informed consent for the use of clinical data for research purposes and the use 
of clinical data was approved by the local ethical review board.  
CSF biochemical analysis 
CSF sampling and analyses followed similar protocols for both sites. In short, 
CSF was obtained by lumbar puncture, using a 25-gauge needle, and collected in 10 
ml polypropylene tubes (Sarstedt, Nümbrecht, Germany). Within two hours, CSF 
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samples were centrifuged at 1800g for 10 minutes at 4° C. CSF supernatant was 
transferred to new polypropylene tubes and stored at -20° C until further analysis 
(within two months). CSF Aβ42 was measured with a commercially available ELISA 
(Innotest β-amyloid(1-42); Fujirebio, Ghent, Belgium) on a routine basis as described 
before [25,26]. 
Sampling plasma and assaying Aβ42 in plasma 
Plasma samples were collected by EDTA-blood collecting tube followed by 
centrifugation with a speed ranges from 1500-2500g for 15 minutes at room 
temperature. The upper layer (plasma) was then transferred and aliquoted to 1.5 ml 
microcentrifuge tube and stored at -70 ℃ or lower until further analysis. Collected 
plasma samples were then delivered to MagQu Co., Ltd. by dry-ice package for 
assaying plasma A42 blindly. 
Plasma A42 concentration was measured by the IMR assay [18,27]. Amyloid β 
1-42 IMR Reagent (Cat. # MF-AB2-0060; MagQu Co., Ltd., Taiwan) is made of 
magnetic nanoparticles (Cat. # MF-DEX-0060; MagQu Co., Ltd., Taiwan) and 
specific antibody (Cat. # ab34376; Abcam, UK) against C-terminal of A42. A fixed 
volume of IMR reagent and plasma sample (60 l: 60 l) were mixed in sample 
testing tube and assayed with magnetic immunoassay analyzer (Cat. # XacPro-S; 
MagQu Co., Ltd., Taiwan) at room temperature. The analyzer detects the reduction 
percentage in the alternating current (ac) magnetic susceptibility ac of IMR reagent 
due to the interaction of antibody-coated magnetic nanoparticles and Aβ42. The 
reduction percentage of ac signal is referred to as the IMR signal. The IMR signal 
was converted to the concentration of A42 according to the relationship between IMR 
signal and A42 concentration [21,27]. It is not necessary to dilute EDTA plasma 
sample for assaying A42 by IMR, because the plasma A42 levels of both control and 
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AD group are within the assaying range of IMR A42 assay (0.77-30,000 pg/ml). 
Interference test of IMR plasma A42 assay by A40 
Sample contained 100 pg/ml of A42 (Cat. # A9810; Sigma-Aldrich; USA) was 
reconstituted and prepared according to user’s manual. 100 pg/ml of A40 (Cat. # 
A1075; Sigma-Aldrich; USA) was used as interference material and then spiked into 
sample contained 100 pg/ml A42. The A42 levels were then determined by IMR 
A42 assay. 
Statistical analysis 
Continuous variables are presented as (mean ± standard deviation). Continuous 
variables were compared using T-test. Spearman correlation done with GraphPad 




The demographic information of subjects enrolled at Sahlgrenska University 
(GOT) and Amsterdam (AMST) is given in Table 1. The mean values and standard 
deviations of CSF A42 level detected with conventional ELISA for each site are also 
shown in Table 1. The average levels of CSF A42 in AD groups at the two sites were 
402.2  105.3 pg/ml (GOT) and 465.2  106.9 pg/ml (AMST), respectively. The CSF 
A42 levels for control groups of the two sites were 901.3  177.2 pg/ml (GOT) and 
979.7  190.6 pg/ml (AMST), respectively. Combining subjects of the two sites, the 
CSF A42 level is 432.2  109.9 pg/ml for AD and 946.9  187.1 pg/ml for CONT, as 
given in Table 2. The combined AD group showed a significantly lower level of CSF 
A42 than the control group (p < 0.001). 
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The specificity of plasma A42 assay by IMR was clarified by spiking its 
similarity, A40, in sample contained A42 as interference material. The measured 
A42 on samples contained A42 only was 115.7 pg/ml. The measured A42 of another 
sample contained both A42 and A40 was quantified to be 104.6 pg/ml. The recovery 
rate of measured A42 by IMR between with and without A40 is 90.4% with a error 
range less than 10%. 
Human plasma contains various and abundant endogenous biomolecules may 
interfere the measurement of IMR assay on plasma A42. The chemicals in medicine 
used to treatment inflammatory diseases, viral and bacterial infections, cardiovascular 
disease and Alzheimer’s disease may also interfere. Each of these common molecules 
and chemicals (10,000 mg/ml of hemoglobin, 600 mg/ml of conjugated bilirubin, 
30,000 mg/ml of intra lipid, 200 mg/ml of uric acid, 500 IU/ml of rheumatoid factor, 
60,000 mg/ml of albumin, 500 mg/ml of acetylsalicylic acid, 300 mg/ml of ascorbic 
acid, 1,000 mg/ml of ampicillin sodium, 100 ng/ml of Quetiapine Fumarate, 90 ng/ml 
of Galanthanmine hydrobromide, 100 ng/ml of Rivastigmine hydrogen tartrate, 1,000 
ng/ml of Donepezil Hydrochloride and 150 ng/ml of Memantine Hydrochloride) are 
spiked in same plasma sample contains 115.7 pg/ml A42 quantified by IMR assay, 
separately. The measured plasma A42 ranges from 104.3 pg/ml to 123.8 pg/ml, and 
the corresponding recovery rate of measured A42 by IMR between with and without 
interfering materials is within 90.1% to 107.0% with a error range less than 10%. 
Taken together, this finding indicates that the A40, biomolecules, drugs and chemicals 
listed above do not interfere with the assay of plasma A42 by IMR. 
In order to validate the dilution linearity of assaying A42 by IMR, a dilution 
recovery study was performed by diluting a plasma sample containing A42 by factors 
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of 5, 10, 20, 50 and 100 with PBS buffer. The measured A42 concentration of the 
original sample (un-diluted) is 1059.43 pg/ml spiked with synthetic A42 in plasma. 
The dilution recoveries for samples diluted 1:5, 1:10, 1:20, and 1:50 ranged from 97.2 
% to 108.9 % with a error range less than 10%. The dilution recovery for sample 
diluted 1:100 was 115.3%. So, the highest linear dilution factor is 50 times. 
The plasma A42 levels assayed with IMR in AD at individual and combined 
cohorts were 17.9  4.0 pg/ml (GOT), 17.9  3.9 pg/ml (AMST), and 17.9  4.3 
pg/ml (combined). In controls, the plasma A42 levels assayed with IMR individual 
and combined sites were 13.7  0.7 pg/ml (GOT), 16.8  1.8 pg/ml (AMST), and 15.5 
 2.1 pg/ml (combined) for CONT. The AD group showed a higher level of plasma 
A42 than the control group (p < 0.001), as shown in Table 2. The increase in plasma 
A42 level in AD patients of these European cohorts assayed with IMR is consistent 
with Taiwan and US studies [18-20]. According to the results in Table 2, the ratio of 
A42 level in plasma to that in CSF was approximately 1.6% for controls and 4.1% for 
AD patients.  
In Table 2, the opposite change in A42 levels in CSF and plasma between 
controls and AD patients is evidenced. The relationship between CSF A42 and 
plasma A42 of the 106 subjects is plotted in Fig. 1, showing a non-linear correlation 
between CSF A42 and plasma A42. Spearman correlations are used to analysis the 
CSF-Plasma A42 correlations in controls and in AD, separately. In controls, there was 
a weakly positive correlation between CSF A42 and plasma A42 levels (r = 0.186). 
However, in AD, there is a moderately negative correlation between CSF A42 and 
plasma A42 levels (r = -0.352). This points out that the plasma A42 level 
dramatically increases with the decreasing CSF A42 level in AD. 
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By combining the control and AD groups, all data points in Figure 1 are fitted to 
hyperbolic curve: 








,                                      (1) 
where  and  are fitting parameters. By fitting the data to Eq. (1), the parameters are 
obtained to be 12.1 and 130.4, respectively. The fitting curve is plotted with the solid 
line in Fig. 1. The meanings of  and  in Eq. (1) are the low-limited values of 
plasma A42 and CSF A42 levels respectively, as plotted with dashed lines in Fig. 1.  
 
DISCUSSION 
To our knowledge, this is the first report showing that plasma A42 levels are 
negatively correlated with CSF A42 levels in AD patients. In contrast, a previous 
study recently reported both plasma and CSF A42 levels dropped in the dementia 
stage when assayed using ultrasensitive digital ELISA methodology (Simoa assay) 
[12]. This means A42 level in plasma and in CSF assayed with Simoa showed a 
slightly positive correlation. The opposite finding of an inverse (negative) correlation 
between CSF and plasma A42 in the current study might be related to the different 
designs of technological platforms used. The Simoa method [12] is based on the 
sandwich assay and thus relies on the binding of two antibodies (capture and detection 
antibody) to measure A42 molecules in body fluids [12,28], with the first antibody 
used to capture the N-terminal of A42, whereas the second antibody binds to the 
C-terminal domain of A. Because plasma A42 is frequently bound to carrier proteins 
in blood, such as albumin or lipoproteins [29], this may induce a potential 
stereoscopically obstacle for two antibodies to associate with one A42 molecule 
simultaneously, with loss of some plasma A42 signal by using two antibodies in 
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sandwich method. In contrast, the IMR method is a single-antibody immunoassay. 
The antibody specifically capturing C-terminal (a.a. 37-42) of A42 is anchored on the 
magnetic nanoparticles to detect A42 molecule. Based on the design of IMR assay, it 
ideally has a higher possibility to capture and detect A42 molecule when C-terminal 
of A42 is exposed in various conformations, such as isolated, complex or oligomeric 
form. This may explain the different signal for IMR in comparison with the 
sandwich-based immunoassay when detecting A42. Another explanation for the 
differing results is that the antibody used in the IMR experiments is a polycloncal 
antibody that has been reported to react with several 25-85 kDa bands of unknown 
identity at western blot of human plasma according to the commercial vendor. It was 
evidenced that IMR A42 assay is specific for A42 in the presence of A40 in present 
study. Whether these are made up from oligomerised A42 or other anti-A-reactive 
proteins remains to be examined.  
In addition to assay methodologies, we propose the following hypothesis from 
the biology point of view to explain the observed negative correlation between plasma 
A42 and CSF A42 levels in this study. CSF A42 shows a significant reduction in AD 
patients as reported in many studies [5-9], probably caused by aggregation and 
deposition of A42 in brain or a defect of A42 clearance which leads to lower amount 
of A42 molecules transport to CSF[30]. In contrast, when plasma A42 levels are 
measured by the IMR technique, there is an increase in AD [18, 20-22], probably 
related to the different transportation systems to move A42 from the brain to the CSF 
and to move A42 from the brain to the peripheral blood. Following is our hypothesis 
to emphasize the impact of independent transportation system on increasing plasma 
A42 levels in AD. 
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It is known that some clearance systems exist for transportation of A42 from 
brain to peripheral blood in order to clean out toxic A42 [31]. The blood-brain barrier 
(BBB) could play a role as a barrier to allow transportation of monomeric and soluble 
forms of A42 to the peripheral blood. The ratio of A42 in plasma as compared with 
CSF is small (< 5%; Table 2), a figure similar to a previous study [32], which may 
indicate that only small portion of A42 born in brain can reach peripheral blood. But 
in AD, the clearance systems might keep working to transport more A42 to peripheral 
blood to avoid more A42 accumulating in brain. This may be one of the reasons that 
A42 level increased in peripheral blood of AD patient in present study. An alternative 
explanation for the inverse correlation between plasma and CSF A42 levels in AD 
patients is the difference in composition of the matrix. The total protein concentration 
in blood plasma is approximately 50-70 g/l for an adult. The blood plasma is abundant 
in albumin (which constitute 50-60% of blood plasma proteins) that may carry 
substantial amounts of A42 [33] as compared with the amount of free A42. Because 
albumin is highly soluble in blood matrix, albumin-A42 complexes may be more 
prone to stay in a soluble form, which may prevent A42 from oligomerization and 
aggregation in blood. When A42 is transported from brain to peripheral blood in AD, 
it is a logical that higher level of soluble A42 in blood plasma are quantified by the 
IMR assay than by a sandwich immunoassay. On the other hand, the total protein 
level in spinal fluid is less than 1% of that in plasma, with albumin levels around 230 
mg/l as compared to 40 g/l in plasma [34]. In this environment with low levels of 
carrier proteins, aggregation-prone A42 molecules may relatively more easily contact 
with each other to form insoluble aggregates, which could reduce levels quantified by 
conventional sandwich immunoassays. On the contrast, IMR assay shows better 
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sensitivity and consistence when quantifying ultra-low concentration of plasma A42 
from various and independent cohorts than conventional ELISA. In order to clarify 
the matrix effect of above interpretation, meanwhile to exclude the divergence 
between methodologies, a study of quantification of CSF A42 and plasma A42 by 
IMR assay form same subjects is necessary for further study. 
 
CONCLUSION 
We demonstrate the correlation between plasma and CSF A42 levels in two 
independent clinical cohorts. While CSF A42 levels were measured using sandwich 
ELISA methods, plasma A42 levels were measured with IMR, which is a technique 
based on a single antibody. A hyperbolic curve was found for the relationship between 
plasma A42 and CSF A42 in the whole set of samples. While plasma and CSF A42 
levels were weakly positive correlated in the control group, a moderately negative 
correlation between plasma and CSF A42 levels was observed within the AD group. 
This negative correlation in AD presented in this study may be caused by the 
differences of assaying methodologies, A42 transportation systems or matrix effect of 
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Figure 1. Relationship between plasma A42 and CSF A42 levels for control (CONT) 
and AD group. The solid line denotes the hyperbolic function with two 





Table 1. The demographic information and CSF A42 level of subjects in this study. 








CONT* 18 71.6  11.3 35.3% 901.3  177.2 




CONT 25 63.1  5.6 32.0% 979.7  190.6 
AD 30 60.4  3.2 53.5% 465.2  106.9 















Table 2. Detected A42 levels in CSF and plasma for subjects in CONT 
and AD groups. 





CONT 43 946.9  187.1 15.5  2.1 1.6% 
AD 63 432.2  109.9 17.9  4.3 4.1% 
Mean  SD; +Detected using conventional ELISA; ++Detected using 
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